Aberra FN - Search Results

1

Risk for active tuberculosis in inflammatory bowel disease patients.

Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Aberra FN, et al. Clin Gastroenterol Hepatol. 2007 Sep;5(9):1070-5. doi: 10.1016/j.cgh.2007.04.007. Epub 2007 Jul 12. Clin Gastroenterol Hepatol. 2007. PMID: 17627901

2

Review article: monitoring of immunomodulators in inflammatory bowel disease.

Aberra FN, Lichtenstein GR. Aberra FN, et al. Aliment Pharmacol Ther. 2005 Feb 15;21(4):307-19. doi: 10.1111/j.1365-2036.2005.02343.x. Aliment Pharmacol Ther. 2005. PMID: 15709982 Free article. Review.

3

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.

Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Aberra FN, et al. Gastroenterology. 2003 Aug;125(2):320-7. doi: 10.1016/s0016-5085(03)00883-7. Gastroenterology. 2003. PMID: 12891531

4

Seasonal variation in flares of inflammatory bowel disease.

Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. Lewis JD, et al. Among authors: aberra fn. Gastroenterology. 2004 Mar;126(3):665-73. doi: 10.1053/j.gastro.2003.12.003. Gastroenterology. 2004. PMID: 14988820

5

Antibiotic use and the risk of flare of inflammatory bowel disease.

Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD. Aberra FN, et al. Clin Gastroenterol Hepatol. 2005 May;3(5):459-65. doi: 10.1016/s1542-3565(05)00020-0. Clin Gastroenterol Hepatol. 2005. PMID: 15880315

6

Methods to avoid infections in patients with inflammatory bowel disease.

Aberra FN, Lichtenstein GR. Aberra FN, et al. Inflamm Bowel Dis. 2005 Jul;11(7):685-95. doi: 10.1097/01.mib.0000160742.91602.b7. Inflamm Bowel Dis. 2005. PMID: 15973124 Review.

7

Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.

Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Osterman MT, et al. Among authors: aberra fn. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1887-93.e3. doi: 10.1016/j.cgh.2014.03.035. Epub 2014 Apr 30. Clin Gastroenterol Hepatol. 2014. PMID: 24793028 Free PMC article. Clinical Trial.

8

Can Colonoscopy Reduce the Risk of Colon Cancer and Mortality in Patients With Inflammatory Bowel Disease?

Aberra FN, Osterman MT, Lewis JD. Aberra FN, et al. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1702-3. doi: 10.1016/j.cgh.2015.02.032. Epub 2015 Feb 25. Clin Gastroenterol Hepatol. 2015. PMID: 25725440 No abstract available.

9

Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.

Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI. Vajravelu RK, et al. Among authors: aberra fn. Inflamm Bowel Dis. 2017 Dec 19;24(1):217-226. doi: 10.1093/ibd/izx019. Inflamm Bowel Dis. 2017. PMID: 29272482 Free PMC article.

10

Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?

Blonski W, Kundu R, Lewis J, Aberra F, Osterman M, Lichtenstein GR. Blonski W, et al. Scand J Gastroenterol. 2008;43(6):698-703. doi: 10.1080/00365520701866150. Scand J Gastroenterol. 2008. PMID: 18569987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page